Tyra Biosciences, Inc. (TYRA) - Q3 2024 10-Q Summary
Business Context and Reporting Period
Tyra Biosciences, Inc. is a clinical-stage biotechnology company developing precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology. The company utilizes its proprietary SNÅP platform to design therapies for targeted oncology and genetically defined conditions. This report covers the quarterly period ended September 30, 2024.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(24.0) million | $(21.2) million | $(60.9) million | $(46.3) million |
| Net Loss Per Share (Basic/Diluted) | $(0.41) | $(0.49) | $(1.08) | $(1.09) |
| Operating Expenses | $28.6 million | $24.0 million | $74.4 million | $54.3 million |
| Interest & Other Income | $4.6 million | $2.8 million | $13.5 million | $8.0 million |
| Cash & Cash Equivalents | $103.9 million (as of Sept 30, 2024) | |||
| Marketable Securities | ||||
| Total Liquidity (Cash + Securities) | $360.1 million (as of Sept 30, 2024) | |||
| Accumulated Deficit | $(225.7) million (as of Sept 30, 2024) |
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses rose by $4.6 million in Q3 2024 compared to Q3 2023, driven primarily by higher stock-based compensation ($2.5 million increase), personnel costs ($1.3 million), and clinical trial support ($1.1 million).
- Higher Net Loss: The net loss increased by $2.9 million in Q3 2024 versus Q3 2023, despite a $1.8 million increase in interest income due to the larger cash balance.
- Capital Raise: In February 2024, the company completed a private placement raising approximately $200 million in gross proceeds, significantly boosting liquidity compared to the prior year.
- Stock-Based Compensation: Total stock-based compensation expense for the nine months ended September 30, 2024, was $16.1 million, compared to $9.3 million in the same period in 2023.
Outlook, Management Commentary, and Risks
- Clinical Progress:
- TYRA-300 (Oncology): Interim data from the SURF301 Phase 1/2 study showed a 100% disease control rate in patients with FGFR3+ metastatic urothelial carcinoma (mUC) at doses ≥ 90 mg QD. The company plans to submit an IND for a Phase 2 study in non-muscle invasive bladder cancer (NMIBC) by year-end 2024.
- TYRA-300 (Achondroplasia): The FDA allowed the IND to proceed for the BEACH301 Phase 2 study in children with achondroplasia. First patient dosing is expected in Q1 2025.
- TYRA-430: The FDA allowed the IND to proceed for a Phase 1 study in hepatocellular carcinoma (HCC) in August 2024.
- Liquidity Outlook: Management believes current cash, cash equivalents, and marketable securities ($360.1 million) are sufficient to fund operations through at least 2026.
- Risks: The company has never generated revenue and expects to incur significant losses for the foreseeable future. Success depends on clinical trial outcomes, regulatory approvals, and the ability to raise additional capital if needed. There are no material legal proceedings pending.
- Subsequent Events: In October 2024, certain investors exchanged 3 million shares of common stock for pre-funded warrants. Additionally, 705,000 pre-funded warrants were exercised in a cashless transaction.
Key Facts for Investor Verification
- Verify the timeline and enrollment status of the upcoming Phase 2 studies for TYRA-300 in NMIBC and achondroplasia.
- Monitor the burn rate relative to the $360.1 million liquidity position to confirm the runway through 2026.
- Review the specific details of the October 2024 exchange of shares for pre-funded warrants to understand potential dilution impacts.
- Track the progression of TYRA-430 into the Phase 1 study for HCC.
- Assess the impact of increasing stock-based compensation on future operating expenses.